The Prevalence, Disease Burden and Prognosis of COPD in Patients With Cardiovascular Diseases -A Multi-center, Prospective, Interventional Study (PRECEDE)
Status: Recruiting
Location: See all (69) locations...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
This is a multi-center, prospective, and interventional study conducted in 3 types of cardiovascular diseases (CVD) subjects , including 3 cohorts which are patients with newly or previously diagnosed coronary heart disease ( CHD), atrial fibrillation ( AF) and chronic heart failure (CHF).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Healthy Volunteers: f
View:
• Give signed written informed consent to participate.
• At least 40 years of age at baseline visit.
• Previous or newly diagnosed by at least one of the 3 types of CVD which are,
‣ Coronary heart disease ( CHD )
⁃ Atrial fibrillation (AF )
⁃ Chronic heart failure ( CHF )
• Subjects have no absolute contraindications to spirometry testing.
• Subjects have the cognitive ability to conduct questionnaires after e valuated by investigators.
Locations
Other Locations
China
Research Site
NOT_YET_RECRUITING
Beijing
Research Site
RECRUITING
Beijing
Research Site
NOT_YET_RECRUITING
Beijing
Research Site
NOT_YET_RECRUITING
Beijing
Research Site
NOT_YET_RECRUITING
Changsha
Research Site
NOT_YET_RECRUITING
Chaohu
Research Site
NOT_YET_RECRUITING
Chengdu
Research Site
NOT_YET_RECRUITING
Chengdu
Research Site
NOT_YET_RECRUITING
Chengdu
Research Site
NOT_YET_RECRUITING
Chongqing
Research Site
NOT_YET_RECRUITING
Dalian
Research Site
NOT_YET_RECRUITING
Dingzhou
Research Site
NOT_YET_RECRUITING
Dongguan
Research Site
NOT_YET_RECRUITING
Foshan
Research Site
NOT_YET_RECRUITING
Fuyang
Research Site
NOT_YET_RECRUITING
Fuzhou
Research Site
NOT_YET_RECRUITING
Guangzhou
Research Site
NOT_YET_RECRUITING
Guangzhou
Research Site
NOT_YET_RECRUITING
Guangzhou
Research Site
NOT_YET_RECRUITING
Guangzhou
Research Site
RECRUITING
Haikou
Research Site
NOT_YET_RECRUITING
Hangzhou
Research Site
RECRUITING
Hangzhou
Research Site
NOT_YET_RECRUITING
Harbin
Research Site
NOT_YET_RECRUITING
Hefei
Research Site
NOT_YET_RECRUITING
Hefei
Research Site
NOT_YET_RECRUITING
Hubei
Research Site
RECRUITING
Jinhua
Research Site
NOT_YET_RECRUITING
Jinzhong
Research Site
RECRUITING
Jiujiang
Research Site
NOT_YET_RECRUITING
Kaiyuan
Research Site
NOT_YET_RECRUITING
Kunming
Research Site
NOT_YET_RECRUITING
Kunming
Research Site
NOT_YET_RECRUITING
Lanzhou
Research Site
NOT_YET_RECRUITING
Leping
Research Site
NOT_YET_RECRUITING
Linhai
Research Site
NOT_YET_RECRUITING
Meizhou
Research Site
NOT_YET_RECRUITING
Mianyang
Research Site
NOT_YET_RECRUITING
Nanchang
Research Site
NOT_YET_RECRUITING
Quanzhou
Research Site
RECRUITING
Shanghai
Research Site
NOT_YET_RECRUITING
Shanghai
Research Site
RECRUITING
Shanghai
Research Site
NOT_YET_RECRUITING
Shanghai
Research Site
NOT_YET_RECRUITING
Shantou
Research Site
NOT_YET_RECRUITING
Shantou
Research Site
NOT_YET_RECRUITING
Shenyang
Research Site
NOT_YET_RECRUITING
Shenzhen
Research Site
NOT_YET_RECRUITING
Shijiazhuang
Research Site
RECRUITING
Suining
Research Site
RECRUITING
Suzhou
Research Site
NOT_YET_RECRUITING
Tai’an
Research Site
NOT_YET_RECRUITING
Taiyuan
Research Site
NOT_YET_RECRUITING
Taiyuan
Research Site
NOT_YET_RECRUITING
Tianjin
Research Site
NOT_YET_RECRUITING
Tianjin
Research Site
NOT_YET_RECRUITING
Tianjin
Research Site
NOT_YET_RECRUITING
Tianmen
Research Site
NOT_YET_RECRUITING
Wuhan
Research Site
NOT_YET_RECRUITING
Wuxi
Research Site
NOT_YET_RECRUITING
Xi'an
Research Site
NOT_YET_RECRUITING
Xiamen
Research Site
NOT_YET_RECRUITING
Xinzheng
Research Site
NOT_YET_RECRUITING
Xuzhou
Research Site
RECRUITING
Yangzhou
Research Site
RECRUITING
Yulin
Research Site
NOT_YET_RECRUITING
Zhangzhou
Research Site
NOT_YET_RECRUITING
Zhengzhou
Research Site
NOT_YET_RECRUITING
Zunyi
Contact Information
Primary
AstraZeneca Clinical Study Information Center
information.center@astrazeneca.com
1-877-240-9479
Time Frame
Start Date: 2025-11-28
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 3000
Treatments
Other: Guideline education and implementation
Related Therapeutic Areas
Sponsors
Leads: AstraZeneca